29883-25-8

Upstream product

• 151367-92-9 L-tert-butyl N-[2,6-dioxohexahydro-3-pyridinyl] Carbamate 
• 56-85-9 L-glutamine 
• 2650-64-8 Cbz-L-Gln 
• 22785-43-9 (S)-benzyl (2,6-dioxopiperidin-3-yl)carbamate 
• 13726-85-7 Boc-Gln-OH 

Downstream Products

• 672883-67-9 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-2,6-dioxo-hexahydropyridine 
• 672883-69-1 (3S)-3-(4-difluoromethoxy-3-methoxyphenylcarboxamido)-2,6-dioxohexahydro-pyridine 
• 672883-64-6 (3S)-3-(3-cyclopentyloxy-4-methoxyphenylcarboxamido)-2,6-dioxohexahydropyridine 
• 1426657-05-7 C₃₇H₆₀N₆O₉Si 
• 1314881-81-6 padanamide B 

Relevant academic research and scientific papers

Preparation method of deuterated intermediate

The present invention provides a preparation method of a deuterated intermediate. The deuterated intermediate has a structure shown by a formula I; the preparation method comprises the following steps: amino groups in a raw material A and an aldehyde grou

Total synthesis of padanamides A and B

The first total syntheses of padanamides A and B have been achieved, unambiguously confirming their structures. The Royal Society of Chemistry.

5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS

Taught are derivatives of 5H-thioeno(3,4-c)pyrrole-4,6-dione, their organic, and inorganic salts, methods of synthesis of these derivatives, and their application as active pharmaceutical-ingredients useful as inhibitors of TNFα, the derivative being represented by the general formula (I): in which R1 represents H, C1-6alkyl, OR4, OC(O)R5, NO2, NHC(O)R6, or NR7R8; R2 represents H, a halogen, or C1-6alkyl; R3 represents H, methyl, isopropyl, allyl, benzyl, CH2CO2(C1-6alkyl), or CH2(CH2)nR9; R4, R5, R6, R7, and R8 each independently and at each occurrence represents H, or C1-6alkyl; R9 represents H, C1-6alkyl, OH, OC1-6alkyl, NH2, NHC1-6alkyl, N(C1-6alkyl)2, or CO2(C1-6alkyl); and n represents 1, 2, 3, or 4.

NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel heterocyclic compounds that inhibit phosphodiesterase type 4 (PDE 4). The compounds are useful for treating inflammatory conditions, diseases of the central nervous systems and insulin resistant diabetes.

Design, synthesis, and preliminary pharmacological evaluation of N-Acyl-3-aminoglutarimides as broad-spectrum chemokine inhibitors in vitro and anti-inflammatory agents in vivo

A series of N-substituted 3-aminoglutarimides have been synthesized and tested for inhibitory activity against a range of chemokines in vitro and for suppression of lipopolysaccharide-induced inflammation in vivo. The results show that they represent the first class of small molecules with broad-spectrum chemokine inhibitory effects. Among the compounds studied, 10 (NR58,4) was the most potent, being active at doses between 5 and 15 nM in vitro and at 0.3 mg kg-1 in vivo.